{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rgp120%2FHIV-1MN", "query": { "intervention": "rgp120/HIV-1MN" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rgp120%2FHIV-1MN&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T06:02:55.811Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00000774", "title": "A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections", "HIV Seronegativity" ], "interventions": [ { "name": "rgp120/HIV-1MN", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1 SF-2", "type": "BIOLOGICAL" }, { "name": "Placebo version of rgp120/HIV-1MN", "type": "BIOLOGICAL" }, { "name": "Placebo version of rgp120/HIV-1SF2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "1 Day", "maximum_age": "3 Days", "sex": "ALL", "summary": "1 Day to 3 Days" }, "enrollment_count": 156, "start_date": null, "completion_date": "1999-01", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-24T06:02:55.811Z", "location_count": 36, "location_summary": "Long Beach, California • Los Angeles, California • San Diego, California + 23 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000774" }, { "nct_id": "NCT00001041", "title": "Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections", "Pregnancy" ], "interventions": [ { "name": "rgp120/HIV-1MN", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "16 Years to 40 Years · Female only" }, "enrollment_count": 24, "start_date": null, "completion_date": "1998-07", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-24T06:02:55.811Z", "location_count": 6, "location_summary": "San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001041" }, { "nct_id": "NCT00001052", "title": "A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Aluminum hydroxide", "type": "BIOLOGICAL" }, { "name": "QS-21", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1MN", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 110, "start_date": null, "completion_date": "1997-09", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-24T06:02:55.811Z", "location_count": 5, "location_summary": "St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 2 more", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001052" }, { "nct_id": "NCT00000853", "title": "A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "rgp120/HIV-1MN", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 37, "start_date": null, "completion_date": "1999-01", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-24T06:02:55.811Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Rochester, New York • Seattle, Washington", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Rochester", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000853" }, { "nct_id": "NCT00000755", "title": "A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "rgp120/HIV-1MN", "type": "BIOLOGICAL" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 168, "start_date": null, "completion_date": "1993-03", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-24T06:02:55.811Z", "location_count": 10, "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000755" }, { "nct_id": "NCT00000762", "title": "A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "rgp120/HIV-1MN", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1 SF-2", "type": "BIOLOGICAL" }, { "name": "gp160 Vaccine (MicroGeneSys)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Month to 18 Years" }, "enrollment_count": 72, "start_date": null, "completion_date": "1996-02", "has_results": false, "last_update_posted_date": "2021-11-03", "last_synced_at": "2026-09-24T06:02:55.811Z", "location_count": 33, "location_summary": "Long Beach, California • Los Angeles, California • Oakland, California + 21 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000762" }, { "nct_id": "NCT00001020", "title": "A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "rgp120/HIV-1IIIB", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1MN", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 28, "start_date": null, "completion_date": "1995-02", "has_results": false, "last_update_posted_date": "2012-05-18", "last_synced_at": "2026-09-24T06:02:55.811Z", "location_count": 3, "location_summary": "St Louis, Missouri • Philadelphia, Pennsylvania • Seattle, Washington", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001020" }, { "nct_id": "NCT00001096", "title": "A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "MN rgp120/HIV-1 and A244 rgp120/HIV-1", "type": "BIOLOGICAL" }, { "name": "QS-21", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1MN", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 60, "start_date": null, "completion_date": "2000-03", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-24T06:02:55.811Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Rochester, New York • Nashville, Tennessee + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001096" }, { "nct_id": "NCT00001026", "title": "A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "gp160 Vaccine (Immuno-AG)", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1IIIB", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1MN", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1 SF-2", "type": "BIOLOGICAL" }, { "name": "HIVAC-1e", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 56, "start_date": null, "completion_date": "1994-12", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-09-24T06:02:55.811Z", "location_count": 2, "location_summary": "Rochester, New York • Seattle, Washington", "locations": [ { "city": "Rochester", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001026" }, { "nct_id": "NCT00002428", "title": "A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "HIV-1 Peptide Vaccine, Microparticulate Monovalent", "type": "BIOLOGICAL" }, { "name": "rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "United Biomedical", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-24T06:02:55.811Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002428" } ] }